{"count": 5, "results": [{"_id": "30828964", "pmid": 30828964, "title": "Delays in anti-hyperglycaemic therapy initiation and intensification are associated with cardiovascular events, hospitalizations for heart failure and all-cause mortality.", "journal": "Diabetes Obes Metab", "authors": ["Nichols GA", "Romo-LeTourneau V", "Vupputuri S", "Thomas SM"], "date": "2019-07-01T00:00:00Z", "doi": "10.1111/dom.13683", "meta_date_publication": "2019 Jul", "meta_volume": "21", "meta_issue": "7", "meta_pages": "1551-1557", "score": 50063.9, "text_hl": "MATERIALS AND METHODS: Using electronic health record data, we created three @DISEASE_Neoplasms_Second_Primary @DISEASE_MESH:D016609 @@@TI@@@ cohorts of @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ @SPECIES_9606 @@@patients@@@ who: 1) initiated @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MET@@@) as their first @<m>DISEASE_HIV_Seropositivity</m> @DISEASE_MESH:D006679 @@@anti-hyperglycaemic@@@ therapy; 2) added a @CHEMICAL_Sulfonylurea_Compounds @CHEMICAL_MESH:D013453 @@@sulfonylurea@@@ (@CHEMICAL_Sulfonylurea_Compounds @CHEMICAL_MESH:D013453 @@@SU@@@) to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MET@@@; and 3) initiated @CHEMICAL_Insulin @CHEMICAL_MESH:D007328 @@@insulin@@@ (@CHEMICAL_Insulin @CHEMICAL_MESH:D007328 @@@INS@@@) while using @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MET@@@ or @CHEMICAL_Sulfonylurea_Compounds @CHEMICAL_MESH:D013453 @@@SU@@@, alone or in combination. ", "citations": {"NLM": "Nichols GA, Romo-LeTourneau V, Vupputuri S, Thomas SM. Delays in anti-hyperglycaemic therapy initiation and intensification are associated with cardiovascular events, hospitalizations for heart failure and all-cause mortality. Diabetes Obes Metab. 2019 Jul;21(7):1551-1557. PMID: 30828964", "BibTeX": "@article{30828964, title={Delays in anti-hyperglycaemic therapy initiation and intensification are associated with cardiovascular events, hospitalizations for heart failure and all-cause mortality.}, author={Nichols GA and Romo-LeTourneau V and Vupputuri S and Thomas SM}, journal={Diabetes Obes Metab}, volume={21}, number={7}, pages={1551-1557}}"}}, {"_id": "29938343", "pmid": 29938343, "title": "Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM).", "journal": "Eur J Clin Pharmacol", "authors": ["Kumar SS", "McManus H", "Radovich T", "Greenfield JR", "Viardot A", "Williams KM", "Cronin P", "Day RO"], "date": "2018-10-01T00:00:00Z", "doi": "10.1007/s00228-018-2506-5", "meta_date_publication": "2018 Oct", "meta_volume": "74", "meta_issue": "10", "meta_pages": "1327-1332", "score": 50044.47, "text_hl": "There was no overall trend in the initiation of antihypertensive and/or anti-hyperlipidaemic agents with respect to the time of @<m>DISEASE_HIV_Seropositivity</m> @DISEASE_MESH:D006679 @@@anti-hyperglycaemic@@@ initiation. ", "citations": {"NLM": "Kumar SS, McManus H, Radovich T, Greenfield JR, Viardot A, Williams KM, Cronin P, Day RO. Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM). Eur J Clin Pharmacol. 2018 Oct;74(10):1327-1332. PMID: 29938343", "BibTeX": "@article{29938343, title={Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM).}, author={Kumar SS and McManus H and Radovich T and Greenfield JR and Viardot A and Williams KM and Cronin P and Day RO}, journal={Eur J Clin Pharmacol}, volume={74}, number={10}, pages={1327-1332}}"}}, {"_id": "27919710", "pmid": 27919710, "title": "The transcription factor carbohydrate-response element-binding protein (ChREBP): A possible link between metabolic disease and cancer.", "journal": "Biochim Biophys Acta Mol Basis Dis", "authors": ["Iizuka K"], "date": "2017-02-01T00:00:00Z", "doi": "10.1016/j.bbadis.2016.11.029", "meta_date_publication": "2017 Feb", "meta_volume": "1863", "meta_issue": "2", "meta_pages": "474-485", "score": 50043.04, "text_hl": "Moreover, in @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@tumor@@@ cells, @GENE_MLXIPL @GENE_58805 @@@ChREBP@@@ promotes aerobic glycolysis through @GENE_TP53 @GENE_7157 @@@p53@@@ inhibition, resulting in @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@tumor@@@ cell proliferation. @<m>DISEASE_HIV_Seropositivity</m> @DISEASE_MESH:D006679 @@@Anti@@@-@DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ and @<m>DISEASE_HIV_Seropositivity</m> @DISEASE_MESH:D006679 @@@anti@@@-lipidemic drugs such as @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, bile acid sequestrants, @CHEMICAL_Docosahexaenoic_Acids @CHEMICAL_MESH:D004281 @@@docosahexaenoic acid@@@ and @CHEMICAL_Eicosapentaenoic_Acid @CHEMICAL_MESH:D015118 @@@eicosapentaenoic acid@@@ may affect @GENE_MLXIPL @GENE_58805 @@@ChREBP@@@ transactivity. ", "citations": {"NLM": "Iizuka K. The transcription factor carbohydrate-response element-binding protein (ChREBP): A possible link between metabolic disease and cancer. Biochim Biophys Acta Mol Basis Dis. 2017 Feb;1863(2):474-485. PMID: 27919710", "BibTeX": "@article{27919710, title={The transcription factor carbohydrate-response element-binding protein (ChREBP): A possible link between metabolic disease and cancer.}, author={Iizuka K}, journal={Biochim Biophys Acta Mol Basis Dis}, volume={1863}, number={2}, pages={474-485}}"}}, {"_id": "22029001", "pmid": 22029001, "pmcid": "PMC3193779", "title": "Choosing a Gliptin", "journal": "Indian J Endocrinol Metab", "authors": ["Gupta V", "Kalra S"], "date": "2011-10-01T00:00:00Z", "doi": "10.4103/2230-8210.85583", "meta_date_publication": "2011 Oct", "meta_volume": "15", "meta_issue": "4", "meta_pages": "298-308", "score": 50038.47, "text_hl": "The treatment of @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes mellitus@@@ (@DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2DM@@@) has included the use of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and @CHEMICAL_Sulfonylurea_Compounds @CHEMICAL_MESH:D013453 @@@sulfonylurea@@@ (@CHEMICAL_Sulfonylurea_Compounds @CHEMICAL_MESH:D013453 @@@SU@@@) as first-line @<m>DISEASE_HIV_Seropositivity</m> @DISEASE_MESH:D006679 @@@anti@@@-@DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ therapies world over since years. ", "citations": {"NLM": "Gupta V, Kalra S. Choosing a Gliptin Indian J Endocrinol Metab. 2011 Oct;15(4):298-308. PMID: 22029001", "BibTeX": "@article{22029001, title={Choosing a Gliptin}, author={Gupta V and Kalra S}, journal={Indian J Endocrinol Metab}, volume={15}, number={4}, pages={298-308}}"}}, {"_id": "19149538", "pmid": 19149538, "title": "Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.", "journal": "Curr Drug Targets", "authors": ["Gupta R", "Walunj SS", "Tokala RK", "Parsa KV", "Singh SK", "Pal M"], "date": "2009-01-01T00:00:00Z", "doi": "10.2174/138945009787122860", "meta_date_publication": "2009 Jan", "meta_volume": "10", "meta_issue": "1", "meta_pages": "71-87", "score": 50036.008, "text_hl": "These drugs have been approved as a once-daily oral monotherapy or as a combination therapy with current @<m>DISEASE_HIV_Seropositivity</m> @DISEASE_MESH:D006679 @@@anti@@@-@DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic agents@@@ like @CHEMICAL_Pioglitazone @CHEMICAL_MESH:D000077205 @@@pioglitazone@@@, @CHEMICAL_Glyburide @CHEMICAL_MESH:D005905 @@@glibenclamide@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ etc. for the treatment of @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2DM@@@. ", "citations": {"NLM": "Gupta R, Walunj SS, Tokala RK, Parsa KV, Singh SK, Pal M. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. PMID: 19149538", "BibTeX": "@article{19149538, title={Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.}, author={Gupta R and Walunj SS and Tokala RK and Parsa KV and Singh SK and Pal M}, journal={Curr Drug Targets}, volume={10}, number={1}, pages={71-87}}"}}]}